--- title: "Women's Health Pharmaceuticals Industry" description: "Women's health pharmaceutical companies develop and sell contraceptives, menopause treatments, fertility drugs and conditions specific to women." canonical: https://www.getswoopr.com/stocks/industries/health-care/women-s-health-pharmaceuticals/ source: "Swoopr Investment: https://www.getswoopr.com" --- # Women's Health Pharmaceuticals Industry ## Direct Answer Women's health pharmaceutical companies develop and sell contraceptives, menopause treatments, fertility drugs and conditions specific to women. Revenue depends on prescribing, payer coverage and the cost of direct-to-consumer marketing. ## Industry Overview Women's Health Pharmaceuticals sits within the health care sector. The first numbers to compare across companies here are prescription volume, net revenue per prescription and payer coverage. The outside forces that move them are listed under Primary Macro Drivers. ## Key Industry Metrics - **Prescription volume**: Number of prescriptions written for contraceptives, menopause and related drugs. Volume growth reflects awareness, access through telehealth and payer coverage. - **Net revenue per prescription**: Average revenue per prescription after discounts and rebates. It indicates pricing power and the effect of coverage and generic alternatives. - **Payer coverage**: Extent to which insurers cover and favor products. Many women's health products are covered by mandate, but placement still shapes uptake. - **Pipeline stage**: Where new candidates sit from early trials to approval. Later stages are closer to launch but cost more, and a single-product company relies on them for future growth. - **Marketing spend as a share of revenue**: Selling and promotion expense relative to sales, including direct-to-consumer advertising. A high share can fuel launches but pressure profit, so compare it with sales growth. ## Primary Macro Drivers - **Menopause and contraception demand**: Demand for hormone treatments and contraceptives follows life stages and changing attitudes toward treatment, which moves prescription volume. - **Insurance coverage mandates**: Laws that require insurers to cover contraceptives or fertility drugs reduce what patients pay, which lifts prescriptions and net revenue per prescription. - **Telehealth and direct-to-consumer channels**: Online prescribing lets companies reach patients without office visits, which can add volume and change the cost of marketing. - **New hormonal and non-hormonal launches**: New hormonal and non-hormonal options expand treated patients and can shift share, so launches move prescriptions and marketing spend. ## Major Risks - **Safety labeling and regulatory actions**: Regulators can require new warnings or limit use of a drug class, which cuts prescriptions quickly; watch label changes and regulator communications. - **Generic competition**: When patents expire, cheaper copies take most of the volume and net price falls; watch the patent timeline for each major product. - **Reimbursement**: Insurers may restrict coverage or require step therapy, which lowers prescription volume or net price; watch coverage decisions. - **Single-product concentration**: A company reliant on one product can be hit hard by setbacks to it; watch product share of total revenue and pipeline stage. ## Industry Characteristics | Characteristic | Profile | | --- | --- | | Cyclicality | Defensive | | Capital Intensity | Medium | | Regulatory Intensity | High | | Industry Maturity | Mature | | Geographic Importance | U.S. / Global | ## Companies Associated with Women's Health Pharmaceuticals The SEC's Standard Industrial Classification has no code that describes women's health pharmaceuticals as a group, so there is no complete list of its filers. The companies below come from Swoopr's SEC dataset and have operations in or next to the industry. Each is classified by the SEC under its own main business. | Company | SEC classification | Revenue | Growth | Net margin | Year | | --- | --- | --- | --- | --- | --- | | [Organon & Co.](https://www.getswoopr.com/stocks/companies/organon-and-co/) | Pharmaceutical Preparations | $6.2 billion | -2.9% | 3.0% | FY 2025 | Source: each company's own annual report as filed with the SEC (XBRL data), figures in U.S. dollars. Listing here describes a business relationship to the industry, not a recommendation. To find more companies, use the [company directory](https://www.getswoopr.com/stocks/companies/) and the [health care hub](https://www.getswoopr.com/stocks/industries/health-care/). ## Where to Go Next The Women's Health Pharmaceuticals guide describes how the industry earns money, what to measure and what can go wrong. To see how it compares, read the neighbouring industries in the same sector, then apply the same checks to a specific company. ### More in Health Care - [Health Care sector overview](https://www.getswoopr.com/stocks/industries/health-care/) - [Wound Care](https://www.getswoopr.com/stocks/industries/health-care/wound-care/) - [Veterinary Services](https://www.getswoopr.com/stocks/industries/health-care/veterinary-services/) - [Ambulatory Surgery Centers](https://www.getswoopr.com/stocks/industries/health-care/ambulatory-surgery-centers/) - [Vaccines](https://www.getswoopr.com/stocks/industries/health-care/vaccines/) - [Animal Health](https://www.getswoopr.com/stocks/industries/health-care/animal-health/) - [Urgent Care](https://www.getswoopr.com/stocks/industries/health-care/urgent-care/) - [Antibody Therapeutics](https://www.getswoopr.com/stocks/industries/health-care/antibody-therapeutics/) - [Telehealth](https://www.getswoopr.com/stocks/industries/health-care/telehealth/) ### Put it to work - [How to analyze a stock](https://www.getswoopr.com/stocks/how-to-analyze-a-stock/) - [Fundamental analysis guides](https://www.getswoopr.com/learn/fundamental-analysis/) - [Company research](https://www.getswoopr.com/stocks/companies/) - [All industries](https://www.getswoopr.com/stocks/industries/) ## Frequently Asked Questions What are the main KPIs for the Women's Health Pharmaceuticals industry? Key performance indicators for the Women's Health Pharmaceuticals industry include: Prescription volume, Net revenue per prescription, Payer coverage, Pipeline stage, Marketing spend as a share of revenue. Which matter most depends on the company's model, so compare them across several companies rather than relying on one. How cyclical is the Women's Health Pharmaceuticals industry? The Women's Health Pharmaceuticals industry is generally defensive, meaning demand tends to remain relatively stable regardless of the economic cycle. Companies in this space can provide portfolio stability during recessions, though growth may lag in strong expansions. What are the biggest risks in the Women's Health Pharmaceuticals industry? The primary risks for Women's Health Pharmaceuticals companies include: Safety labeling and regulatory actions, Generic competition, Reimbursement, Single-product concentration. Investors should assess each company's exposure to these factors and its track record of navigating them. **[Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/)** Swoopr's editorial team produces independent investment education content reviewed for accuracy and clarity. We do not provide personalized financial advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).